NYSE$UHS

Universal Health Services Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

UHS's financial performance showed improvement in Q2 2023, with increased revenues and earnings compared to the same period last year.

Universal Health Services, Inc. reported a 6.8% increase in net revenues, reaching $3.548 billion in Q2 2023. Net income attributable to UHS was $171.3 million, or $2.42 per diluted share, compared to $164.1 million, or $2.20 per diluted share, in Q2 2022. Adjusted net income was $179.4 million, or $2.53 per diluted share.

  • Net revenues increased by 6.8% to $3.548 billion.
  • Net income attributable to UHS was $171.3 million, or $2.42 per diluted share.
  • Adjusted net income attributable to UHS was $179.4 million, or $2.53 per diluted share.
  • The company is increasing the lower end of its guidance range for consolidated net revenues, Adjusted EBITDA, and adjusted EPS for the year ended December 31, 2023.

Headline financials

Total Revenue

$3.55B

Previous: $3.32B+6.8%
EPS (adj)

$2.53

Previous: $2.20+15.0%
Avg Licensed Beds

6.6K

Previous: 7.0K-5.0%
Avg Available Beds

6.5K

Previous: 6.8K-5.1%
Patient Days

384.4K

Previous: 376.0K+2.2%
Avg Daily Census

4.2K

Previous: 4.1K+2.2%
Occupancy Licensed Beds

63.8%

Previous: 59.3%+7.6%
Occupancy Available Beds

65.5%

Previous: 60.8%+7.7%
Admissions

79.1K

Previous: 76.7K+3.1%
Length of Stay

4.9

Previous: 4.9+0.0%
BH Avg Licensed Beds

24.2K

Previous: 24.3K-0.6%
BH Avg Available Beds

24.1K

Previous: 24.2K-0.6%
BH Patient Days

1.6M

Previous: 1.6M+0.9%
BH Avg Daily Census

17.5K

Previous: 17.3K+0.9%
BH Occupancy Licensed

72.2%

Previous: 71.1%+1.5%
BH Occupancy Available

72.5%

Previous: 71.4%+1.5%
BH Admissions

119.7K

Previous: 116.6K+2.6%
BH Length of Stay

13.3

Previous: 13.4-0.7%
Capital Expenditures

-$337M

Previous: -$408M+17.5%
Free Cash Flow

-$165M

Previous: -$244M+32.2%
Net Income

$171M

Previous: $164M+4.4%
Operating Income

$280M

Previous: $233M+20.0%
Gross Profit

$3.55B

Previous: $3.32B+6.8%
Cash & Equivalents

$79.5M

Previous: $133M-40.1%
Total Assets

$13.7B

Previous: $13.3B+3.3%
Stock-Based Comp

$22.1M

Previous: $22.6M-2.2%

Revenue & EPS history

UHS · Revenue · Quarterly

$3.55B

Q2 2023+6.8%vs Q2 2022
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

UHS · $3.55B total across 2 segments · Q2 2023

  • Acute Care Services
    $2B+6.8%
  • Behavioral Health Services
    $1.54B+7.6%

Forward guidance

UHS revised its 2023 operating results forecasts, increasing the lower end of the guidance range for consolidated net revenues, Adjusted EBITDA net of NCI, and adjusted net income attributable to UHS per diluted share. The higher end of the 2023 guidance range for these metrics remains substantially unchanged.

Tailwinds

  • Net revenues are forecasted between $14.130 billion and $14.330 billion.
  • Adjusted EBITDA, net of NCI, is expected to be between $1.696 billion and $1.756 billion.
  • Adjusted EPS – diluted is projected to be between $9.85 and $10.50 per share.
  • The revised forecast excludes the impact of certain future items that are nonrecurring or non-operational in nature.
  • The forecast is subject to conditions set forth in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures.

Headwinds

  • The forecast excludes the impact of potential future items, including unrealized gains/losses on equity securities.
  • The forecast is subject to potential material items such as reserves for various matters, legal judgments, and lawsuits.
  • Potential impacts of non-ordinary course acquisitions, divestitures, and joint ventures are excluded.
  • Costs related to extinguishment of debt and gains/losses on sales of assets and businesses are not included.
  • Impairments of goodwill, long-lived and intangible assets are excluded from the forecast.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+0.3%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+0.7%

Avg return

30 days after

49%

34 / 69 earnings

Positive

+17.5%

Q3 2022

Best reaction

-13.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-9.5%-7.0%-16.4%
Q4 2025-5.5%-1.0%-9.9%
Q3 2025+2.5%+1.4%+14.1%
Q2 2025-0.2%+3.3%+7.3%
Q1 2025-0.6%+3.4%+10.5%
Q4 2024+3.3%-3.8%+3.4%
Q3 2024-13.4%-12.1%-15.5%
Q2 2024+10.6%+17.3%+25.8%
Q1 2024+0.1%+2.6%+6.9%
Q4 2023-1.6%+4.1%+11.0%
Q3 2023-0.2%-0.6%+11.4%
Q2 2023-4.6%-6.5%-12.3%
Q1 2023+1.5%+6.9%-9.3%
Q4 2022-9.1%-13.5%-15.5%
Q3 2022+17.5%+25.8%+39.3%
Q2 2022-1.5%+1.3%-5.7%
Q1 2022-5.7%-7.8%-8.1%
Q4 2021+8.6%+8.7%+11.1%
Q3 2021-7.0%-8.5%-5.0%
Q2 2021+4.2%+5.1%+1.6%
Q1 2021+0.3%+2.0%+10.1%
Q4 2020-9.1%-6.2%-2.0%
Q3 2020+3.0%+11.1%+24.2%
Q2 2020+0.9%+1.7%+0.2%
Q1 2020+3.7%-2.5%+8.6%
Q4 2019-5.3%-2.7%-34.3%
Q3 2019-4.6%-4.0%-3.6%
Q2 2019+10.9%+11.6%+4.7%
Q1 2019-0.8%-2.6%-5.5%
Q4 2018+3.9%+2.7%+0.1%
Q3 2018-5.3%-1.0%+8.0%
Q2 2018+9.3%+9.3%+12.0%
Q1 2018-4.6%-5.2%-3.2%
Q4 2017-1.3%+5.3%+0.7%
Q3 2017-6.9%-8.3%-9.9%
Q2 2017-9.2%-10.3%-12.6%
Q1 2017-2.0%-0.1%-3.0%
Q4 2016-0.9%-0.8%-0.8%
Q3 2016+0.6%-0.7%+1.3%
Q2 2016-4.4%-5.2%-12.1%
Q1 2016+2.1%
Q4 2015+2.4%
Q3 2015+2.4%
Q2 2015+2.1%
Q1 2015-0.7%
Q4 2014+3.8%
Q3 2014-1.0%
Q2 2014+6.8%
Q1 2014+8.3%
Q4 2013-2.6%
Q3 2013+2.6%
Q2 2013+3.3%
Q1 2013+3.3%
Q4 2012-0.0%
Q3 2012-3.2%
Q2 2012+4.8%
Q1 2012-1.7%
Q2 2011+2.0%
Q4 2011+2.0%
Q3 2011+3.8%
Q1 2010+3.8%
Q4 2010+3.8%
Q1 2011+3.8%
Q2 2010+5.0%
Q3 2009+0.0%
Q3 2010+0.0%
Q4 2009-0.3%
Q2 2009-0.3%
Q4 2008-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro